BCDA insider trading
NasdaqCM HealthcareBioCardia, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About BioCardia, Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths products. It has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. It also has a development and commercialization agreement with CART-Tech, B.V. for the development of Heart3D Fusion Imaging system. BioCardia, Inc. is based in Sunnyvale, California.
Company website: www.biocardia.com
BCDA insider activity at a glance
FilingIQ has scored 180 insider transactions for BCDA since Nov 1, 2016. The most recent filing in our index is dated Apr 29, 2026.
Across the full history, 123 open-market purchases
and 3 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on BCDA insider trades is 59.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest BCDA Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for BCDA?
- FilingIQ tracks 180 Form 4 insider transactions for BCDA (BioCardia, Inc.), covering filings from Nov 1, 2016 onwards. 5 of those were filed in the last 90 days.
- Are BCDA insiders net buyers or net sellers?
- Across the full Form 4 history for BCDA, 123 transactions (68%) were open-market purchases and 3 (2%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does BCDA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is BCDA in?
- BioCardia, Inc. (BCDA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $11.99M.
Methodology & sources
Every BCDA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.